

CARACO PHARMACEUTICAL LABORATORIES LTD  
Form 8-K  
April 20, 2005

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT  
Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934

April 14, 2005  
(Date of report)

CARACO PHARMACEUTICAL LABORATORIES, LTD.  
(Exact name of registrant as specified in its charter)

Michigan  
(State or other jurisdiction  
of incorporation)

0-24676  
(Commission file number)

38-2505723  
(I.R.S. employer  
identification no.)

1150 Elijah McCoy Drive, Detroit, Michigan 48202  
(Address of principal executive offices)

(313) 871-8400  
(Registrant's telephone number, including area code)

Not Applicable  
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 140.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 5.02. Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.**

(a) Not Applicable;

(b) On April 14, 2005, William C. Brooks resigned as a director of Caraco because his business and other activities did not leave him sufficient time for future meetings of the Board. Mr. Brooks was one of the three independent directors of the Company. The Company is actively searching for a new independent director to bring it into compliance with the Amex requirement that it have a minimum of three independent directors on its audit committee.

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**CARACO PHARMACEUTICAL LABORATORIES, LTD.**

Date: April 20, 2005

By: /s/ Jitendra N. Doshi

Jitendra N. Doshi  
Chief Executive Officer

---